CION: What The 2031 Notes Actually Solved, And What Still Sits In The 2026-2027 Debt Wall
The 2031 notes extended CION's duration and were meant to pay down secured facilities, but they did not erase the company's debt wall. After the deal, roughly $114.8 million of Series A notes still sits in 2026 and about $627.5 million remains concentrated in 2027.
The main article already argued that funding was buying CION time. This follow-up isolates a narrower question: how much time was actually bought, and against which part of the maturity schedule. That distinction matters because the 2031 deal can look, on a first read, like a transaction that wipes away the 2026-2027 wall. In practice, it solved only part of the story.
The core point: the 2031 notes were not a full refinancing of the debt wall. They replaced one layer of the liability structure. In February 2026 CION issued $135 million of unsecured notes due March 31, 2031, at a fixed 7.50% coupon. But the stated use of proceeds was to pay down borrowings under secured credit facilities, not to directly take out the Series A notes due in August 2026 and not to directly neutralize the full 2027 stack.
That changes the read at two levels. First, 2026 did not disappear. At year-end 2025 CION still had about $114.8 million of Series A notes due on August 31, 2026, and the February 2026 interest-reset report is a reminder that this piece remained floating-rate debt until maturity. Second, the real issue does not sit in 2026 at all. It sits in 2027, where $300 million of JPM borrowings, $200 million of Floating Rate Notes, $47.5 million of 7.41% notes, and another $80 million of institutional term loans all come due. That is a debt wall, not a loose end.
What 2031 Actually Solved
To understand what happened in February 2026, it helps to start in December 2025. That was when CION issued $172.5 million of unsecured notes, split between $125 million due 2029 at 7.70% and $47.5 million due 2027 at 7.41%. That December deal had already been used to repay the $125 million notes due in February 2026. In other words, part of the near-term cleanup had already happened before the 2031 issuance.
The February 2026 2031 deal came with a different job. The pricing notice dated February 2, 2026 referred to $125 million of gross issuance, about $121.25 million of net proceeds after underwriting discounts and commissions and before estimated offering expenses, and a 30-day over-allotment option for another $18.75 million. By the time the annual report was filed, the final result was clear: on February 9, 2026 the company issued and sold $135 million, including $10 million placed through the full exercise of the over-allotment option. The notes carry a fixed 7.50% coupon, trade on the NYSE, and are callable only from March 31, 2028.
That matters because the stated use of proceeds was to pay down borrowings under the company's senior secured credit facilities. So this was a duration and liability-mix move. It reduced reliance on secured funding and increased the unsecured layer. It was not a transaction that erased the 2027 wall. It was a transaction that shifted part of the balance between secured and unsecured debt.
| Item | What the filings show | What it means in practice |
|---|---|---|
| 2031 issuance | $135 million, 7.50% coupon, maturity on March 31, 2031 | A new long-dated funding layer |
| Stated use of proceeds | Paydown of borrowings under secured credit facilities | Some relief on the secured side, not a direct wipeout of 2026 and 2027 |
| February 2026 notes | $125 million had already been repaid in December 2025 via the 7.70% and 7.41% issuance | Part of the near-term problem was solved before 2031 |
| Series A | About $114.8 million due on August 31, 2026 | 2026 still exists, just in a narrower form |
The Debt Wall That Did Not Disappear
Note 8 gives the debt map as it stood at year-end 2025, just before the 2031 notes were issued. That remains the right starting point for understanding concentration because the company does not disclose how much of the February 2026 proceeds actually went to JPM and how much went to UBS. So the filing gives direction, but not a fully updated post-deal debt map.
The 2026 problem is smaller, but it is not gone. The only remaining piece there is the Series A notes, roughly $114.8 million, due on August 31, 2026. This is no longer the February 2026 issue, but it is still a maturity point inside the next twelve months. More importantly, the Series A notes continue to carry a floating rate of SOFR plus 3.82%. In the immediate report dated February 10, 2026, the company calculated the interest for the November 30, 2025 through February 27, 2026 interest period at 1.85581% for the period. In other words, even as CION extended duration on one side of the balance sheet, it still carried floating debt into 2026 on the other.
The real issue remains 2027. That year still contains roughly $627.5 million:
- $300 million under the JPM Credit Facility, due June 15, 2027
- $200 million of Floating Rate Notes, due November 8, 2027
- $47.5 million of 7.41% notes, due December 15, 2027
- $50 million of the 2022 Term Loan, due April 27, 2027
- $30 million of the 2024 Term Loan, due September 30, 2027
That changes the interpretation of the 2031 issuance. Even under a very generous assumption that most of the new proceeds first go to reducing JPM, 2027 still remains a very heavy year. The filings give enough to show the direction of relief, but not enough to claim that the debt wall disappeared. It did not.
What Changed In The Liability Mix
This is the core of the continuation. The 2031 deal was not designed to be a dramatic cost-of-funding victory. It looks much more like a structural transaction.
During 2025, CION's weighted average interest rate was 7.26% on JPM, 7.11% on UBS, 7.97% on the Series A notes, 8.59% on the Floating 2027 notes, 7.73% on the 2022 Term Loan, and 8.03% on the 2024 Term Loan. Against that backdrop, the 2031 notes came at a fixed 7.50%. So the right question is not whether CION suddenly found cheap money. The company mainly bought time, fixed one slice of the funding stack, and tried to move part of the capital structure from secured debt toward unsecured debt.
That has two sides. On the positive side, there is a clear benefit in reducing reliance on asset-backed secured lines. The March 2026 presentation highlights $1.106 billion of unencumbered assets, and at year-end 2025 the debt mix was roughly 35% secured and 65% unsecured. If the 2031 proceeds were used as stated, that mix shifts even further toward unsecured funding. That can improve balance-sheet flexibility.
But this is also where equity risk rises. Longer-dated unsecured debt can ease immediate pressure on pledged assets, yet it also leaves CION more dependent on ongoing access to the unsecured credit market and on portfolio stability, because NAV, asset coverage, and future refinancing capacity all have to hold up through the 2027 test. This is no longer just a collateral question. It is a market-access and portfolio-stability question.
Why This Is Still Equity Risk
The annual report sends a two-sided signal here. On one hand, the company says that at year-end 2025 it had about $124.2 million of cash and short-term investments and another $100 million available under secured financing arrangements, and it states that liquidity and capital sources are expected to be sufficient for near-term needs. On the other hand, the same section says the company cannot be certain that these sources of funds will be available in the future at acceptable times, on acceptable terms, and in sufficient amounts. That is not a technical contradiction. It is an admission that time has been bought, but only conditionally.
That has to be read alongside the leverage metrics. In the March 2026 presentation, debt-to-equity at Q4 2025 was 1.61x, net debt-to-equity was 1.44x, and NAV per share had declined to $13.76. In the annual report, asset coverage was 1.62x, against a 150% minimum that appears across several debt instruments. That is compliance, but it is not a cushion large enough to make 2027 irrelevant. If portfolio quality weakens further, that margin can tighten faster than a surface read suggests.
There is one more point. Even after extending duration, the company continued to declare monthly distributions of $0.10 per share for each month from January through June 2026. This is not an argument against the payout policy. It is a reminder that the new financing does not sit alone. It sits alongside maturities, coupons, financing costs, and shareholder distributions. So from an equity perspective, the 2031 issuance did not close the debate. It simply moved it from the question of whether there is a pressure point in 2026 to the question of how stable the framework will be when 2027 arrives.
Conclusion
The 2031 issuance solved a real problem, but a narrower one than the first read suggests. It extended duration, added an unsecured 2031 layer, and likely reduced some pressure on the secured facilities. That gives CION more room to maneuver.
But this was not a full refinancing of the debt wall. 2026 still contains about $114.8 million of Series A notes, and 2027 still carries roughly $627.5 million of concentrated maturities. So the 2031 notes did not remove the next financing test. They moved it forward and changed its shape. The question is no longer whether the company survived the next maturity. The question is whether it has built a liability structure that can get through 2027 without creating fresh pressure on NAV, covenants, and the equity cushion beneath the debt stack.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.